Quick Answer
Sana Biotechnology, Inc. reported Operating Income Loss of -$250.32 million for the year ending 2025.
- Sana Biotechnology, Inc. showed an increase of +8.2% in Operating Income Loss from 2024 to 2025.
- This data is from Sana Biotechnology, Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 7 years of available data (2019 to 2025), Sana Biotechnology, Inc.'s Operating Income Loss has declined by 77.3%.
- Historical annual values: Fiscal year 2025: -$250.32 million | Fiscal year 2024: -$272.72 million | Fiscal year 2023: -$293.14 million | Fiscal year 2022: -$272.56 million | Fiscal year 2021: -$356.91 million | Fiscal year 2020: -$286.15 million | Fiscal year 2019: -$141.15 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: